Most life sciences and B2B companies know they need stronger marketing. Fewer know specifically where the gap is. They experience the symptoms — slow pipeline development, low win rates, inconsistent messaging, poor launch performance, customer retention that is lower than it should be — without a clear picture of which part of the marketing function is generating them. The result is investment in the wrong places: more trade show presence when the positioning is the problem, more content when the sales enablement is the problem, more digital spend when the customer understanding is the problem.
A marketing needs assessment is the diagnostic that identifies where the gap is before the investment is made. It maps the current state of the marketing function across the full range of capabilities that commercial performance requires, identifies where the function is strong and where it is weak, and produces a prioritized investment recommendation that connects the gaps to the commercial outcomes they are causing.
The Eight Dimensions of Marketing Readiness
Portfolio and product strength is the foundation. Marketing cannot build a strong commercial presence for a weak product portfolio, and a strong product portfolio without effective marketing will underperform its commercial potential.
Product management process determines whether the marketing function has the discipline and infrastructure to manage the portfolio systematically. Organizations without a defined product management process consistently experience product positioning failures, launch delays, and lifecycle management problems.
Brand and messaging determines whether the organization has a coherent, differentiated brand identity and the messaging architecture to express it consistently. A brand strategy playbook — a documented framework that defines the brand’s positioning, voice, visual standards, and key messages — is the infrastructure that ensures consistency across teams, regions, and channels.
Strategic targeting determines whether the organization has the process and data infrastructure to identify and prioritize the right customers.
Marketing execution capability determines whether the organization has the team, tools, and process infrastructure to execute the commercial plan at the quality and scale required.
Customer advocacy and evidence determines whether the organization has systematically captured the customer outcomes and testimonials that build commercial credibility.
Go-to-market readiness determines whether the organization has the commercial infrastructure to execute effective launches.
Measurement and analytics determines whether the organization has the data infrastructure to track marketing performance across the full range of mechanisms through which marketing generates commercial value.
Conducting the Assessment
A rigorous marketing needs assessment combines three sources of input: structured interviews with marketing, sales, and commercial leadership; review of existing marketing materials, metrics, and process documentation; and direct input from customers and prospects about their perception of the brand and the quality of the commercial experience.
The combination of internal and external input is what gives the assessment its diagnostic value. Internal perspectives reveal where the organization believes it is strong and where it believes it has gaps. Customer perspectives reveal whether those beliefs are accurate — and they frequently are not. The most common finding is that the organization overestimates the clarity and distinctiveness of its brand positioning from the customer’s perspective.
We work with life sciences and B2B companies to conduct this assessment and translate its findings into an actionable investment plan. If the symptoms described in this article are familiar — slow pipeline, inconsistent messaging, underperforming launches, or customer retention that falls short of what the product quality should support — the assessment is a practical starting point for identifying the specific interventions that will make the most difference.
Marketing Readiness Scorecard
| Dimension | Strong | Weak | Priority Flag |
|---|---|---|---|
| Portfolio and Product Strength | Competitive, well-supported portfolio with defined lifecycle management; products are clearly differentiated in target segments | Portfolio has strong technology but weak commercial positioning; lifecycle management is reactive; competitive position is eroding | High — positioning and lifecycle investment required before other marketing investment compounds effectively |
| Product Management Process | Defined NPD process with stage-gate discipline; clear ownership of product strategy; structured launch planning | No formal NPD process; launch planning begins too late; product positioning is developed by sales rather than marketing | High — process infrastructure is the prerequisite for consistent launch and lifecycle performance |
| Brand and Messaging | Brand strategy playbook exists and is actively maintained; messaging is consistent across teams, regions, and channels | No brand playbook; different teams communicate different brand identities; messaging varies by channel and individual | High — inconsistent messaging prevents brand equity accumulation regardless of other investment |
| Strategic Targeting | Current persona documentation; defined segment priorities; account intelligence available to sales team in actionable format | No formal personas; all customers treated as equivalent; sales team defines its own targeting without marketing support | Medium-High — targeting precision directly affects pipeline quality and sales efficiency |
| Marketing Execution Capability | Sufficient team and tools for planned commercial activities; planning process connects execution to strategic priorities | Team is under-resourced for planned activities; execution is driven by urgency rather than strategy | Medium — execution quality limits the return on upstream strategic investment |
| Customer Advocacy and Evidence | Systematic process for capturing customer outcomes; active case study and testimonial library; reference customer program | No systematic capture process; customer outcomes are documented informally or not at all | Medium-High — evidence gaps limit credibility at the evaluation stage and increase sales cycle length |
| Go-to-Market Readiness | Defined launch process with stage-gate milestones; sales readiness assessed before launch; channel activation planned in advance | Launches are operationally driven; positioning is finalized after launch; sales team is not equipped before products reach the market | High for companies with active launches — launch positioning failures are expensive and slow to correct |
| Measurement and Analytics | Marketing performance tracked across multiple mechanisms; data connects marketing investment to commercial outcomes | Marketing is evaluated primarily on activity metrics; no connection between marketing investment and commercial outcomes | Medium — measurement gaps prevent optimization and make it difficult to justify investment in the highest-return mechanisms |
MKA Strategic Implication
MKA Insights works with life sciences and B2B companies to conduct marketing needs assessments and translate findings into actionable investment plans. If the symptoms described above are familiar, contact us.